Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MB 106

Next Previous
Search
Drug Profile

MB 106

Alternative Names: CD20-targeted CAR T cell therapy; MB-106; MB-106 CD20 CAR - Mustang Bio

Latest Information Update: 07 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Preclinical Autoimmune disorders

Most Recent Events

  • 07 Aug 2024 Preclinical trials in Autoimmune disorders in USA (IV), before August 2024 (Mustang Bio pipeline, August 2024)
  • 29 Jul 2024 Mustang Bio terminates a phase I/II trial in Non-Hodgkin's lymphoma and Chronic-lymphocytic-leukaemia (Second-line therapy or greater) in USA, due to business reasons (NCT05360238)
  • 17 Jun 2024 Updated efficacy and safety data from a phase I/II trial in Non-Hodgkin's and Chronic-lymphocytic-leukemia released by Mustang Bio

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top